Company profile: Spring Bank Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of small molecule nucleic acid hybrid-based therapeutics and immuno-oncology candidates, including FS118, a LAG-3/PD-L1 mAb2 bispecific antibody in Phase 2 for head and neck cancer, NSCLC and DLBCL; FS120, an OX40/CD137 dual agonist mAb2 in Phase 1; FS222, a CD137/PD-L1 mAb2 in Phase 1 for PD-L1-low tumors; and SB 11285, an IV second-generation STING agonist in Phase 1, alone and with atezolizumab.
Products and services
- FS118: A clinical-stage LAG-3/PD-L1 mAb² bispecific antibody in Phase 2 trials for head and neck cancer, NSCLC, and DLBCL, co-targeting immune checkpoints via the mAb² format
- SB 11285: A second-generation STING agonist for intravenous administration undergoing Phase 1 study as monotherapy and in combination with atezolizumab in oncology
- FS120: A dual-agonist OX40/CD137 mAb² bispecific antibody in Phase 1 trials, aiming to improve standard care treatments by targeting OX40 and CD137 simultaneously
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Spring Bank Pharmaceuticals
NanoCures
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology and infectious disease immunity platforms, including: Cures Platform targeting specific genomic and molecular pathways to yield multiple therapeutics; Data/AI Platform using biometric, genomic, molecular, and environmental data with AI/ML to detect diseases early and guide new cure development; and Developer Platform offering resources, data, and tools to lower barriers and encourage innovation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NanoCures company profile →
Marinomed Biotech
HQ: Austria
Website
- Description: Provider of biopharmaceutical therapies via patent-protected platforms, including MAVIREX-based products against respiratory viruses and the Marinosolv solubilization technology (available for partnerships via Solv4U). Portfolio includes Carragelose, Budesolv, Tacrosolv, and pipeline programs MAM-1004-2 (autoimmune gastritis) and MAM-1001-4 nasal spray.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Marinomed Biotech company profile →
Now Diagnostics
HQ: United States
Website
- Description: Provider of rapid, single-drop-of-blood diagnostic tests delivering results within minutes, including ADEXUSDx assays for COVID-19 antibodies, hCG for early pregnancy, syphilis antibodies, elevated acetaminophen, H-FABP for myocardial damage, and methanol detection in blood, plasma, or serum.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Now Diagnostics company profile →
Amicrobe
HQ: United States
Website
- Description: Provider of advanced biomaterials to prevent and treat infections, offering Amicidin-α Surgical gel for clean and clean-contaminated surgical procedures; Amicidin-β Solution for contaminated and infected tissues with tissue cleansing and microbicidal activity; Amicidin-α PFC for military prolonged field settings (up to 72 hours); and Amicidin-β/EF for emergency settings, including trauma and emergency cesarean delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amicrobe company profile →
Friz Biochem
HQ: Germany
Website
- Description: Provider of advanced electronic biochips and offerings integrating the complete workflow of molecular diagnostics; privately held, founded in October 2004 and based in Neuried near Munich.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Friz Biochem company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Spring Bank Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Spring Bank Pharmaceuticals
2.2 - Growth funds investing in similar companies to Spring Bank Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Spring Bank Pharmaceuticals
4.2 - Public trading comparable groups for Spring Bank Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →